Ali A. Al-Mubarak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali A. Al-Mubarak has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Adriaan Alexander Voors
Department of Cardiology, University Medical Center Groningen University of Groningen Groningen The Netherlands
2 shared publications - Nils Bomer
Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2 shared publications - Peter van der Meer
Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
2 shared publications - Dirk Jan van Veldhuisen
Department of Cardiology, University Medical Centre Groningen, University of Groningen, the Netherlands (D.J.v.V.).
1 shared publication - George Markousis-Mavrogenis
University of Heidelberg
1 shared publication - Gerasimos Filippatos
National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece
1 shared publication
Latest Publications
- 14 May 2024
- Published by University of Groningen Press
Selenium and heart failure
- 14 September 2023
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 21 (2) , 119-149
Immunomodulation and immunopharmacology in heart failure
The immune system is intimately involved in the pathophysiology of heart failure. However, it is currently underused as a therapeutic target in the clinical setting. Moreover, the development of novel immunomodulatory therapies and their investigation for the treatment of patients with heart failure are hampered by the fact that currently used, evidence-based treatments for heart failure exert multiple immunomodulatory effects. In this Review, we discuss current knowledge on how evidence-based treatments for heart failure affect the immune system in addition to their primary mechanism of action, both to inform practising physicians about these pleiotropic actions and to create a framework for the development and application of future immunomodulatory therapies. We also delineate which subpopulations of patients with heart failure might benefit from immunomodulatory treatments. Furthermore, we summarize completed and ongoing clinical trials that assess immunomodulatory treatments in heart failure and present several therapeutic targets that could be investigated in the future. Lastly, we provide future directions to leverage the immunomodulatory potential of existing treatments and to foster the investigation of novel immunomodulatory therapeutics.
- 14 September 2023
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 21 (2) , 119-149
Immunomodulation and immunopharmacology in heart failure
The immune system is intimately involved in the pathophysiology of heart failure. However, it is currently underused as a therapeutic target in the clinical setting. Moreover, the development of novel immunomodulatory therapies and their investigation for the treatment of patients with heart failure are hampered by the fact that currently used, evidence-based treatments for heart failure exert multiple immunomodulatory effects. In this Review, we discuss current knowledge on how evidence-based treatments for heart failure affect the immune system in addition to their primary mechanism of action, both to inform practising physicians about these pleiotropic actions and to create a framework for the development and application of future immunomodulatory therapies. We also delineate which subpopulations of patients with heart failure might benefit from immunomodulatory treatments. Furthermore, we summarize completed and ongoing clinical trials that assess immunomodulatory treatments in heart failure and present several therapeutic targets that could be investigated in the future. Lastly, we provide future directions to leverage the immunomodulatory potential of existing treatments and to foster the investigation of novel immunomodulatory therapeutics.
- Open Access
A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure
Selenium is an essential micronutrient, and a low selenium concentration (80% of patients with low selenium (sensitivity of 44%, specificity of 80%). Given that selenium and iron overlap in their physiological roles, we evaluated the shared determinants and prognostic associates. Both deficiencies shared similar clinical characteristics, including the model risk factors and, in addition, a low protein intake and high levels of C-reactive protein. Low selenium was associated with a similar or worse prognosis compared to iron deficiency. In conclusion, although it is difficult to exclude low selenium based on clinical characteristics alone, we provide a prediction tool which identifies heart failure patients at higher risk of having a low selenium status.
Open AccessA Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure
Selenium is an essential micronutrient, and a low selenium concentration (80% of patients with low selenium (sensitivity of 44%, specificity of 80%). Given that selenium and iron overlap in their physiological roles, we evaluated the shared determinants and prognostic associates. Both deficiencies shared similar clinical characteristics, including the model risk factors and, in addition, a low protein intake and high levels of C-reactive protein. Low selenium was associated with a similar or worse prognosis compared to iron deficiency. In conclusion, although it is difficult to exclude low selenium based on clinical characteristics alone, we provide a prediction tool which identifies heart failure patients at higher risk of having a low selenium status.